Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. is trading at $2.06, down 0.96% on the session. The 50 day average sits at $1.96 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 55.3, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $2.02 with resistance near $2.10, so that band frames the current range. Average daily movement is roughly $0.13, or about 6.2% of the share price, which is what any stop placement has to allow for. The overall health score of 61 out of 100 combines a trend score of 48, momentum of 82 and a risk score of 52.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.